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Abstract
Background: Since the sterilising activity of new antituberculosis drugs is difficult to assess by
conventional phase III studies, surrogate methods related to eventual relapse rates are required.
Methods:  A suitable method is suggested by a retrospective analysis of viable counts of
Mycobacterium tuberculosis in 12-hr sputum collections from 122 newly diagnosed patients with
pulmonary tuberculosis in Nairobi, done pretreatment and at 2, 7, 14 and 28 days. Treatment was
with isoniazid and streptomycin, supplemented with either thiacetazone (SHT) or rifampicin +
pyrazinamide (SHRZ).
Results: During days 0–2, a large kill due to isoniazid occurred, unrelated to treatment or HIV
status; thereafter it decreased exponentially. SHRZ appeared to have greater sterilising activity
than SHT during days 2–7 (p = 0.044), due to rifampicin, and during days 14–28, probably due
mainly to pyrazinamide. The greatest discrimination between SHRZ and SHT treatments was found
between regression estimates of kill over days 2–28 (p = 0.0005) in patients who remained positive
up to 28 days with homogeneous kill rates. No associations were found between regression
estimates and the age, sex, and extent of disease or cavitation. An increased kill in HIV seropositive
patients, unrelated to the treatment effect, was evident during days 2–28 (p = 0.007), mainly during
days 2–7.
Conclusions:  Surrogate marker studies should either be in small groups treated with
monotherapy during days 2 to about 7 or as add-ons or replacements in isoniazid-containing
standard regimens from days 2 to 28 in large groups.
Background
The aim of the Global Alliance for Tuberculosis Drug De-
velopment, formed during 2000, is to discover and test
new antituberculosis drugs, particularly those that have
high sterilising activity and are therefore likely to be able
to shorten the duration of treatment [1]. Unfortunately,
the phase III clinical trials necessary to establish efficacy
in human disease need large numbers of patients, take
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several years to perform, and even then may fail to estab-
lish the activity of the new drug, since the action of a sin-
gle new drug is difficult to detect in multi-drug regimens.
The end-point of conventional phase III trials is the re-
lapse rate after treatment. Surrogate markers for relapse
are therefore required to obtain a preliminary indication
of efficacy and sterilising activity of the drug, even
though a phase III trial with estimation of relapse rates is
eventually necessary. The best validated surrogate mark-
er for relapse is the proportion of sputum cultures that
remain positive after about 2 months of chemotherapy.
This has been shown to associate with the fall in relapse
rates resulting from the addition of rifampicin and
pyrazinamide to regimens of other drugs in 8 clinical tri-
als [2,3]. Less well validated procedures are the meas-
urement of the 85B (alpha) antigen of M. tuberculosis
during chemotherapy [4] and the frequency of positive
cultures at 28 days using the BACTEC system [5]. All of
these markers measure the bactericidal activity of drugs
during periods of at least 15 days of treatment. Studies of
early bactericidal activity (EBA) have usually been car-
ried out over the first 2 days of treatment. They then
measure the activity of different drugs and different dos-
es of the same drug against rapidly multiplying extra-cel-
lular M. tuberculosis in cavity walls but do not indicate
sterilising activity [6,7]. However, a recent multi-centre
study explored a period of 5 days from the start of treat-
ment and found that the extended EBA over the period
from 2 to 5 days might have measured the high sterilising
activity of rifampicin [8].
The possibility of exploring the relative efficiencies of
measures of bactericidal activity during various periods
of chemotherapy arose from a unique study in Nairobi of
counts of viable M. tuberculosis in sputum, cultured in
the same manner as in EBA studies [9]. These counts
were done on 122 patients during the first month of
treatment with either streptomycin, thiacetazone and
isoniazid (SHT) or with streptomycin, isoniazid, ri-
fampicin and pyrazinamide (SHRZ) given daily. Fortu-
nately, they included counts after 2 days of treatment,
the critical time point from which to measure sterilising
activity as indicated in the recent EBA study extended
over a period of 5 days [8]. A comparison between the
bactericidal activities of different periods of treatment
with these regimens would measure the effect of an add-
on to streptomycin/isoniazid (SH) of either thiaceta-
zone, a non-sterilising drug, or of rifampicin and pyrazi-
namide, the two most active sterilising drugs rifampicin
and pyrazinamide [10]. Many of these patients were HIV
seropositive, and the HIV status of all was known, so that
the influence of HIV serology could also be studied. The
main aim of the original report on this study was to ex-
amine the effect of HIV status on the response to chem-
otherapy. The data files from this study were still
available and have been re-analysed principally to see
what differences could be found between the two treat-
ment regimens in respect of EBA responses during the
period of 2–7 days, and of responses over later periods
during treatment. Highly significant differences between
the bactericidal activities of the two regimens were found




Consecutive patients were recruited from the Infectious
Diseases Hospital, Nairobi, who were 15 yr or older, with
newly diagnosed, previously untreated pulmonary TB.
All the patients gave informed consent to participation in
the study and HIV antibody testing. The study was ap-
proved by the Kenya National Ethical Committee. Only
those patients who were culture positive with drug-sen-
sitive M. tuberculosis before treatment were analysed.
These patients were also recruited into a prospective
study of HIV and tuberculosis in which a wide range of
clinical, laboratory, and epidemiological factors were ex-
amined [21].
HIV serology was performed using two enzyme immu-
noassays (EIA), as described previously [9]. Poster-
oanterior chest radiographs were divided horizontally by
eye into three equal zones per lung field. The extent of
disease was determined by the number of zones contain-
ing lesions in the lung parenchyma. The number of lung
zones with cavities was also recorded. Two treatment
regimens were examined sequentially. During the first
month, all drugs were given daily, 7 days in the week. Pa-
tients given the SHT regimen received HT as isoniazid
300 mg and thiacetazone 150 mg, and those given the
SHRZ regimen received the HRZ as a combined prepara-
tion ("Rifater", Merrel-Dow). Streptomycin 1 g was given
intramuscularly in both regimens.
Bacteriology
Bacteriological culture was similar to that described in
previous EBA studies [8]. Sputum was collected in wide-
mouthed glass jars over a 12-h period, from 8 p.m. to 8
a.m. the next day on Days 0, 2, 7, 14, and 28. Therapy was
started immediately following collection of the Day-0
specimen and thereafter was given daily after 8 a.m. Dos-
age and sputum collection times were so arranged that
patients had received 2 daily doses of treatment before
the 2-day time collection, 7 daily doses before the 7-day
collection and so on. Middlebrook 7H11 (Difco Code
0838), supplemented with oleic acid-albumen-catalase
(OADC, Difco Code 0722), was used for the viable
counts. It was made selective by the addition of 200 u/ml
of polymixin B, 100 mg/L of carbenicillin, 10 mg/L of tri-
methoprim, and 10 mg/L of amphotericin B (Mast, CodeBMC Pulmonary Medicine 2001, 1:2 http://www.biomedcentral.com/1471-2466/1/2
MS24) [22]. The sputum was homogenized by adding
glass balls (15 mm diameter) to the glass jar, which was
sealed in a plastic bag and shaken mechanically for 10
min. A 1-ml sample of the homogenized sputum was
mixed with 2 ml diluted dithiothreitol (Sputasol®; Oxoid
Code SR89) and then vortex mixed for 30 s. The mixture
of sputum and dithiothreitol was allowed to stand for 15
min and again vortex mixed. An inoculum of 0.05 ml
from each of a series of five 10-fold dilutions of the spu-
tum mixture was spread onto a one-third segment of
a7H11 agar plate. The plates were sealed in polyethylene
bags and incubated at 37°C for up to 4 wk in air and in
darkness. Following incubation, colonies were counted
on dilutions yielding between 10 and 100 colonies. The
colony counts were analysed as log10 colony forming
units (CFU) / ml undiluted sputum.
The kill index (KI) and regression coefficients (b)
No attempt was made to give specimens that were una-
vailable or gave a negative culture an arbitrary cfu score
since a negative culture could indicate a score anywhere
between the value for 1 colony (1.78 log cfu/ml) and mi-
nus infinity; the results on these specimens were not
used in the anlysis. For each of the intervals between
sputum collections, a kill index (KI) was calculated as the
decrease in the count of colony forming units (cfu) per
day between the counts at the two time points indicated
in parenthesis, without using counts at intermediate
time points. Thus, for the sputum collections over the
first two days of treatment KI (0-2) = (log10 cfu/ml pre-
treatment - log10 cfu/ml at 2 days)/ 2 and during the in-
terval between day-2 and day-28, KI (2-28) = (log10 cfu/
ml at 2 days - log10 cfu/ml at 28 days)/26. A KI was cal-
culated for each of the 10 possible time intervals. Coeffi-
cients of the linear regression of log10 cfu / ml sputum on
days of treatment (b) were calculated when counts were
available at more than two time points, for instance, on
the counts at 2, 7 and 14 days.
Statistical analysis
The results were analysed in EpiInfo, version 6.0 (Cent-
ers for Disease Control, Atlanta, GA) for distributions,
calculation of individual regression coefficients (b) for
each patient and multiple regression analyses, and in
STATA, release 6.0 (College Station, Texas, TX) for Sha-
piro-Wilk tests for normality [23], t-tests with unequal
variances and 2-way analyses of variance (anova) on un-
balanced blocks. In calculating means and SDs, the sign
of b was reversed to make comparisons with the KI val-
ues easier. Since the values of KI (0–2), KI (0–7) and b
(2 onwards) departed considerably from normality in the
Shapiro-Wilk tests with skewed means and high kurto-
sis, the values of KI (0–2) and KI (2–7) were normalised
for anova using the mean symmetry version of the Box-
Cox transformation [24]. Values of b (2 onwards) were
normalised by transformation to 1/(1-b)2, in which 1-b
avoided a mix of positive and negative values but left the
anova unaltered, while the remaining part of the trans-
formation was chosen using the empirical approach of
the ladder command in STATA [25]. All transformed val-
ues and the remaining KIs with different ranges were
found not to depart significantly from normality by the
Shapiro-Wilk test.
Results
The study was done between April 1989 and December
1990. There were 122 patients with cfu counts values at
any time available, but the numbers of patients with
counts at each sampling time decreased by 33 (27%) of
the 122 at 2 days and finally by 54 (44%) at the 28-day
period (Table 1). In some instances, sputum gave a nega-
Table 1: Patients with sputum specimens not available or negative on culture
Duration of treatment (days) Patients (n = 122)
Not available Culture negative
No. % No. %
02 1.6 0 0
23 3 27.0 0 0
74 4 36.1 2 2
14 45 36.9 8 7
28 54 44.3 20 16BMC Pulmonary Medicine 2001, 1:2 http://www.biomedcentral.com/1471-2466/1/2
tive culture, but in many instances, the result was una-
vailable for a variety of reasons that could not be
identified, including failure to cough up sputum, drying
up of the specimen, breakage of sputum containers and
failure of compliance by the patient. Positive HIV serolo-
gy was found in 17 (25%) of 67 patients treated with SHT
and in 20 (36%) of 55 treated with SHRZ. The incidence
of negative and unavailable cultures was fairly similar in
all of the four subgroups of patients. A comparison of the
characteristics of the patients in the SHT series and the
SHRZ series (Table 2) shows no statistically significant
differences in their age, sex or initial severity of disease.
A similar comparison (Table 2) between HIV seronega-
tive and seropositive patients, shows fewer lung zones
involved, less cavitation and lower sputum cfu counts in
those who were seropositive, as previously reported [9].
Regression analyses
Two measures of the rate of kill, KI and b (with sign re-
versed), have been used for clarity in nomenclature, but
both measure the same daily rate of fall of cfu counts.
Each KI is based solely on the two cfu counts indicated in
brackets, while b is based on cfu counts at more than two
points times. The cfu counts on sputum from groups of
patients, each of whom had a complete set of results over
the period that they remained positive are set out in Fig
1. The results from the 34 patients with counts at 0, 2, 7,
14 and 28 days are plotted separately from those of the
20 patients with counts at 0, 2, 7 and 14 days but with un-
available or negative cultures at 28 days, and so on. In all
groups there was an initial abrupt fall in counts of about
1 log unit during the first 2 days. Thereafter, from 2 days
onwards, the counts fell more slowly and appeared line-
arly related to log cfu. However, the slope of the fitted
lines appeared to be steeper when counts became una-
vailable or negative early in treatment. Mean values of b
± SD for all available patients were 0.263 ± 0.245 for the
8 patients in the 7-day group, 0.165 ± 0.099 for the 24
patients in the 14-day group and 0.077 ± 0.049 for the 41
patients in the 28-day group. The difference between the
mean values of b for the 7-day and 14-day groups is not
significant but, between the 14-day and the 28-day
groups, it is highly significant (t test with unequal vari-
ances; p = 0.0002). Since the rates of sputum conversion
of the 14-day and 28-day groups were different, we ex-
plored the cfu counts graphically during treatment in the
"pure" 28-day population. A comparison of the mean cfu
counts during treatment with SHT and SHRZ suggests
that the greatest difference in the slopes occurs during
the 2–7 day interval, not during 7–14 days, and then
again in the 14–28 day interval (Fig. 2). A similar com-
parison of the graphs according to HIV status also shows
that the greater tendency for counts to fall in the serop-
ositive group occurs during days 2–7, while the curves
remain parallel thereafter (Fig. 3). In both Figs 2 and 3,
the data points in each curve fall in an approximately lin-
ear manner from day-2 onwards.
The steep fall in cfu counts over the first 2 days of treat-
ment was calculated as the KI (0–2) in Table 3. The mean
fall in counts was 0.513 per day; no significant differenc-
es were found due either to the difference between SHT
and SHRZ or the difference in HIV status. None of the
contrasts due to treatment or to HIV status attained sta-
tistical significance with any value of the KI starting from
the pretreatment count, that is KI (0–7), KI (0–14) or KI
(0–28). The fitting of linear regression lines from day-0
was not appropriate because of the high values of KI (0–
2).
The regression coefficients for straight lines from 2 to 28
days were then calculated for each patient's data. For the
Table 2: Pretreatment characteristics of patients according to 
treatment series and HIV status
SHT SHRZ HIV- HIV+
No. of patients 67 55 85 37
Mean age 30.0 30.3 29.5 31.5
Per cent males 59.7 60.0 61.2 56.8
Mean lung zone (Max. 6) 4.37 4.15 4.48 3.78*
Mean cavitation (Max. 6) 1.31 1.29 1.65 0.51†
Mean initial log cfu count 6.84 6.72 6.95 6.34 ¶
* p = 0.007 †p = 0.000001 ¶p = 0.007
Figure 1
Mean cfu counts during chemotherapy in patients who had
complete sets of counts up to 2 days of treatment, or up to 7
days or 14 days or 28 days of treatment, but in each case no
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calculation of b (2 onwards) in Table 3, all values of b
were analysed including those with counts available at
28 days, or only up to 7 or 14 days; some had missing in-
termediate counts but were included. When examined by
2-way anova, the difference between the means of b of
0.095 for the 44 SHT patients and 0.163 for the 31 SHRZ
patients was highly significant (p = 0.004) as was the dif-
ference between the mean of 0.099 for the 52 seronega-
tive patients and 0.177 for the 23 seropositive patients (p
= 0.007). However, values of this b contained a high pro-
portion of data from patients who only had positive cul-
tures in the early weeks of treatment and therefore had a
fairly high SD (0.116). Further analyses were then done
to look at the treatment and HIV effects during time pe-
riods of various durations. The KI (2–7) also showed
more rapid killing by the SHRZ than the SHT regimens
and also more rapid killing by seropositive than by se-
ronegative patients, but the differences for both con-
trasts bordered on significance (p = 0.044 and p = 0.051,
respectively). Further analyses of KI values were done for
the later time intervals. The means for KI (2–7), KI (7–
14) and KI (14–28) fell successively from 0.220 to 0.071,
as did their SDs. In KI (7–14) the means for treatment
and HIV status were similar and neither contrast at-
tained significance. However, in the KI (14–18) results,
the treatment mean for SHT patients was 0.053, half that
of 0.099 for SHRZ patients, and the contrast was sugges-
tive (p = 0.1). Correlation between values of the KI (2–7)
and the KI (14–28) in 35 patients gave r = 0.34, a non-
significant association (p = 0.1–0.05).
Finally, the time periods were extended to the 2–28 day
interval. The b (2–28) was calculated on patients all of
whom had 28-day counts; there were 35 patients with
counts at 2, 7, 14 and 28 days, 4 patients with missing 7-
day counts and 5 patients with missing 14-day counts. In
both the b(2–28) and the KI (2–28) results, the mean de-
crease in the SHT regimen was about half that in the
SHRZ regimen, and the SDs of 0.048 and 0.054 are sim-
ilar and lower than those encountered in any earlier
analysis. The treatment effects of more rapid killing by
SHRZ than by SHT in both distributions are highly sig-
nificant, with higher values of the variance ratio F of 14.4
for the b (2–28) distribution than of 9.9 for the KI (2–
28). No interaction was found between the treatment
and HIV status effects in any 2-way anova.
Sputum conversion at 28 days
In view of the established value of sputum conversion at
2-months as a predictor of the increase in sterilising ac-
tivity of a regimen by addition of rifampicin and pyrazi-
namide, the value of sputum conversion at 28 days was
examined in Table 4. Considering only those specimens
which gave either a negative or positive culture result, a
positive culture was obtained from 29 (81%) of 36 SHT
patients and from 19 (59%) of 32 SHRZ patients (p = 0.1)
and also from 38 (78%) of 49 HIV seronegative patients
and from 10 (53%) of 37 HIV seropositive patients (p =
0.08).
Influence of patient characteristics on regression
Multiple regression analyses were carried out relating
age, sex, number of lung zones, number of cavities and
pretreatment cfu count to the KI (0–2), KI (2–7) and
b(2–28). In general no significant associations were
found. However, there was a significant regression be-
tween the pretreatment counts and KI (0–2), and anoth-
er between the 2-day counts and KI(0–2) in the opposite
direction, arising because they are not independent.
Figure 2
Mean cfu counts during treatment with the STH and the
SHRZ regimens in patients who had a complete set of spu-
tum cfu counts up to and including 28 days. Figure 3
Mean cfu counts during treatment in HIV-negative and HIV-
positive patients who had a complete set of sputum cfu
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Discussion
The first important finding was the occurrence of a high
kill during the first 2 days of treatment shown by the KI
(0–2) mean of 0.513. This was probably due to the daily
300 mg isoniazid in both regimens, since isoniazid has a
considerably higher EBA over the first 2 days than other
drugs.[6,7] This mean is only a little lower than the mean
of 0.575 (95% Confidence limits = 0.515 - 0.636) in
pooled results obtained with 300 mg isoniazid daily at
Stellenbosch University, Cape Town [11]. The SD was
however 0.554, considerably higher than the SD of 0.214
in the Cape Town data. These discrepancies might be due
to a few patients having had undetected medication with
isoniazid before admission to the study, which would re-
sult in a low and variable KI (0–2). A negative KI was
found in 9 of 87 patients, of whom 7 had a value of < -0.2.
No urine tests for isoniazid metabolites were done on ad-
mission. It is clear that the high and variable kill over the
first two days swamps any differences between the steri-
lising effects of the two regimens and any due to HIV sta-
tus, and renders useless any regression estimate starting
at day-0.
From day-2 onwards, the 2–7 day period showed just
significant effects in the treatment comparison. The fail-
ure to obtain more clear cut differences, despite being
based on 68 patients, is due to the high SD (± 0.22) of KI
(2–7), which seems to arise from heterogeneity of kill
rates early in treatment (Fig 1). Since heterogeneity is a
major factor, only a moderate increase in precision can
be expected should more precise estimates of kill rates be
obtained by doing counts at intervals during the 2–7 day
period. In contrast, substantial differences have been
found over the 2–5 day period in comparisons of mono-
therapy with isoniazid or rifampicin in EBA studies, even
though much smaller groups of about 10 patients were
examined [8]. This discrepancy suggests that it will be
more difficult to establish the sterilising activity of a new
drug in the early days of treatment by adding it to an iso-
niazid-containing regimen than by testing it in mono-
therapy.
Between 2 and 7 days, it is likely that some phenotypical-
ly sensitive organisms occasionally had spurts of metab-
olism and so were killed preferentially by rifampicin in
the SHRZ group [12]. Thereafter between 7 and 14 days,
the differential between the means for two regimens dis-
appeared perhaps because the original population had
been largely replaced by organisms that are phenotypi-
cally resistant [13]. From 14 to 28 days it seems probable
that killing started again. This biphasic killing seems to
be on different patient populations, because of the poor
correlation between the KI (2–7) and the KI (14–28). We
suggest that this second phase is due mainly to the steri-
lising activity of pyrazinamide, for two reasons: (1)
pyrazinamide in the mouse starts by being less bacteri-
cidal than other drugs, such as isoniazid and streptomy-
cin, but continues at much the same slow rate after the
kill by other drugs has almost stopped (Fig 4) [14]. A
cross-over point occurs at about 25 days after the start of
treatment when the kill due to pyrazinamide begins to
predominate. (2) in pulmonary tuberculosis, mono-
therapy with pyrazinamide has no apparent bactericidal
activity during the first 2 days [6,15] and thereafter has
slow bactericidal activity up to 14 days with a reduction
of sputum cfu counts of only about 1.6 log units [6,16].
Presumably this kill continues after 14 days in human
disease, as in the mouse, without the slowing of the rate
of kill found with other drugs. As shown in clinical stud-
ies, the kill due to pyrazinamide must be substantial [10]
and must terminate by 8 weeks [17,18]; presumably it
therefore occurs somewhere between 14 and 56 days.
Table 3: Summary statistics and main effects of treatment or HIV status in selected distributions
Variable & range (days) KI (0–2) b (2 onwards) KI(2–7) KI (7–14) KI (14–28) b (2–28) KI (2–28)
Mean* (& no. of patients) 0.513(87) 0.123 (75) 0.161 (68) 0.094 (60) 0.071 (43) 0.077 (44) 0.081 (44)
Standard deviation* 0.554 0.116 0.220 0.123 0.072 0.048 0.054
Mean* (& no. of patients):
SHT 0.540 (49) 0.095 (44) 0.121 (42) 0.091 (38) 0.053 (26) 0.057 (27) 0.060 (27)
SHRZ 0.479 (38) 0.163 (31) 0.225 (26) 0.099 (22) 0.099 (17) 0.109 (17) 0.115 (17)
HIV- 0.526 (59) 0.099 (52) 0.124 (48) 0.086 (44) 0.072 (34) 0.076 (34) 0.079 (34)
HIV+ 0.486 (28) 0.177 (23) 0.250 (20) 0.114 (16) 0.066 (9) 0.080 (10) 0.087 (10)
2-way anova†
Treatment F (& p) 0.3 (0.6) 8.8 (0.004) 4.2 (0.044) 0.0(1.0) 2.7 (0.1) 14.4(0.0005) 9.9 (0.003)
HIV status F (& p) 0.01 (0.9) 7.7 (0.007) 4.1 (0.051) 0.4 (0.5) 0.1 (0.7) 0.01 (0.9) 0.20 (0.7)
* Means and standard deviations of untransformed data. † Transformed data for KI (0–2), KI (2–7) and for all values of b except b(2–14). All interac-
tions between treatment and HIV status were not significant. Statistically significant main effects (p < 0.05) are in bold type.BMC Pulmonary Medicine 2001, 1:2 http://www.biomedcentral.com/1471-2466/1/2
In both the KI (0–28) values based only on the 2-day and
28-day counts and in the b (2–28) values based on all
counts in patients with positive 28-day cultures, highly
significant differences for the treatment effect are evi-
dent, with greater killing by the SHRZ regimen. The b
(2–28) values are more efficient than those of the KI (2–
28), but the increase in efficiency is not that large in view
of the greater amount of work that is necessary to obtain
them. The high efficiency of the 2–28 day estimates ap-
pears due partly to the long time period, but mainly to
improved homogeneity of kill rates, as those patients
who converted early and also contributed to high early
SDs were lost from analysis. These findings support the
view, derived from associations between 2-month cul-
ture positivity and the addition of sterilising drugs [2,3],
that sterilising activity is best shown in a small propor-
tion of patients who convert late.
The high efficiency obtained with regression techniques
is to be compared to the failure to show any clear effect
of the treatment contrast or the HIV status contrast on
the proportions of patients with positive cultures at 28
days. The failure is to be expected since the results of
negative/positive culture contrasts at 1-month in clinical
trials were much less efficient than those at 2-months in
detecting the addition of sterilising drugs [3], and the
number of patients, 86 in all, was too small.
The effects of HIV status had a different time course to
the treatment effects. HIV status had no effect during the
first 2 days but a just detectable effect during days 2–7,
with a higher kill in those that were HIV seropositive.
That the HIV effect only occurs early is also shown by the
high significance (p = 0.007) of the HIV contrast in val-
ues of b (2 onwards), which includes early converters,
but by the non-significance of the b (2–28) or the KI (2–
28) contrasts, which do not include early converters. The
effect is small probably because the great majority of ba-
cilli are extra-cellular in cavities, well away from profes-
sional immune cells [19,20]. Since there was no
interaction between the HIV status and treatment ef-
fects, further studies of determinants of the immune re-
sponse during the first 2 days of therapy with isoniazid-
containing regimens, and even in the succeeding week,
are unlikely to yield results helpful to the study of drug-
action. Furthermore, there is no reason to exclude HIV-
positive patients, or even to identify them, in studies of
EBA or in longer-term studies of sterilising activity based
on cfu counting in sputum.
In conclusion, these results suggest that identification of
the sterilising activity of new drugs could most profitably
be done either by EBA studies with monotherapy extend-
ing over, at most, the period of 2–9 days after the start of
treatment with about 12 patients in each treatment
group. It seems unlikely that they could detect differenc-
es by adding a new drug to regimens containing isoni-
azid, nor would they detect sterilising activity similar to
that of pyrazinamide. The alternative would be to study
add-on or replacement regimens by serial cfu counts on
sputum collections starting at day-2 and continuing to
day-28 and probably beyond to day-56, in groups of 60
patients or more.
Conclusions
1. A rapid fall in cfu counts occurred during the first 2
days of treatment, probably due mainly to isoniazid.
Thereafter cfu counts fell approximately exponentially.
2. The fall in cfu counts over days 2–7 was slightly great-
er in the SHRZ than in the SHT regimen. This difference
was probably due to rifampicin in view of the low the bac-
tericidal activity of pyrazinamide at the time.
Table 4: Sputum conversion at 28 days.
SHT SHRZ HIV- HIV+
N o t  a v a i l a b l e 3 1 2 33 61 8
Sputum culture: negative 7 13 11 9
positive 29 19 38 10
Total patients 67 55 85 37
Figure 4
The bactericidal actions of pyrazinamide/isoniazid (HZ) and
streptomycin, PAS and isoniazid (SPH) in the spleens of mice.
Redrawn from Text-fig. 4 in reference 26.BMC Pulmonary Medicine 2001, 1:2 http://www.biomedcentral.com/1471-2466/1/2
3. Calculations of the daily fall in cfu counts over days 2–
28 was a powerful method of demonstrating the long
term bactericidal (sterilising) activities of rifampicin and
pyrazinamide in the SHRZ regimen.
4. No relation was found between clinical measures of
pretreatment severity of disease and the assessments of
sterilising activity.
5. Bactericidal activity during the early period from 2
days onwards was greater in HIV seropositive than in se-
ronegative patients but this did not affect the difference
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